SciELO - Scientific Electronic Library Online

 
vol.22 issue1METABOLIC SYNDROME PREVALENCE AND ASSOCIATED FACTORS IN PERSONAL HEALTH CITY GOVERNMENT OF THE CITY OF EL ALTO - (4050 M.S.N.M.), 2013SÍNDROME DEL LÓBULO MEDIO: REPORTE DE UN CASO author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista Médica La Paz

On-line version ISSN 1726-8958

Abstract

MURILLO NAVARRO, Luis Alejandro  and  MAMANI TARQUI, Jeannett. FIBROSIS PULMONAR IDIOPÁTICA, TRATAMIENTO CON PIRFENIDONA. Rev. Méd. La Paz [online]. 2016, vol.22, n.1, pp.36-41. ISSN 1726-8958.

Idiopathic pulmonary fibrosis is the most frequent type of interstitial pneumonia. It is characterized by an abnormal healing process, with excess fibrous tissue. It is a chronic, progressive illness, limited to the lungs with unknown etiology; it affects adults over 50 years old, with a progressive deterioration of lung function and gas exchange and a fatal outcome in a relatively short period. It has been published a new consensus document of the ATS/ERS/JRS/ALAT, about the diagnostic and treatment of these disease, and it is been suggested as a treatment a new drug that has generated great expectations, pirfenidone. It has anti-inflammatory and anti-fibrotic properties with promising results. we report the case of a patient of 60 years of age admitted to university hospital social security with an insidious respiratory symptoms, during her hospitalization she was diagnosed with idiopathic pulmonary fibrosis with clinical imaging and histopathological criteria. Treatment with Pirfenidone was initiated as recommended by consensus; monitoring the evolution and the fifth month of treatment was favorable.

Keywords : pulmonary fibrosis; pirfenidona.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License